9,677 results match your criteria included antidepressant

Predictors of long-acting injectable antipsychotic prescription at discharge in patients with schizophrenia and other psychotic disorders.

Int Clin Psychopharmacol 2021 Jul 21. Epub 2021 Jul 21.

Department of Psychiatry, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Long-acting injectable antipsychotics (LAIs) increase drug compliance and offer a reliable treatment option with stable pharmacokinetics. The aim of our study is to examine the rate and predictors of LAIs' prescription at discharge in inpatients with schizophrenia and other psychotic disorders. This retrospective study included 400 inpatients. Read More

View Article and Full-Text PDF

Patients with higher vitamin D levels show stronger improvement of self-reported depressive symptoms in psychogeriatric day-care setting.

J Neural Transm (Vienna) 2021 Jul 25. Epub 2021 Jul 25.

Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Margarete-Höppel-Platz 1, 97080, Würzburg, Germany.

Depression is a common psychiatric disorder among geriatric patients that decreases the quality of life and increases morbidity and mortality. Vitamin D as a neuro-steroid hormone might play a role in the onset and treatment of depression. In the present study, the association between depressive symptoms and vitamin D concentration in serum was evaluated. Read More

View Article and Full-Text PDF

Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management.

Cancer Chemother Pharmacol 2021 Jul 24. Epub 2021 Jul 24.

Department of Medical Oncology, Cochin Hospital, AP-HP, Paris, France.

Background: The risk of drug-drug interactions (DDI) has become a major issue in cancer patients. However, data in sarcoma patients are scarce. We aimed to evaluate the frequency and the factors associated with DDI with antitumor treatments, and to evaluate the impact of a pharmacist evaluation before anticancer treatment. Read More

View Article and Full-Text PDF

Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report.

Neuropsychiatr Dis Treat 2021 14;17:2333-2345. Epub 2021 Jul 14.

Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Objective: To develop clinically meaningful improvement thresholds in both the 17-item and the 6-item Hamilton Rating Scale for Depression (HRSD) total scores in depressed outpatients.

Methods: The post-hoc analysis included all adult outpatients with non-psychotic major depressive disorder in the STAR*D trial who entered and exited the first treatment step (up to 14 weeks of citalopram) with a complete set of study measures at baseline and exit and at least one post-baseline measure. Within-patient change and linear regression anchor-based analyses were conducted to define meaningful and substantial changes in the HRSD and HRSD using three patient-reported outcomes [Work and Social Adjustment Scale (WSAS), Quality of Life Enjoyment and Satisfaction-Short Form (Q-LES-Q-SF); Mini-Q-LES-Q] obtained at baseline and exit from the first treatment step in STAR*D. Read More

View Article and Full-Text PDF

Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders.

PLoS One 2021 22;16(7):e0255192. Epub 2021 Jul 22.

Vitos Hochtaunus, Friedrichsdorf, Germany.

Introduction: The aim of this study was to describe the number and type of drugs used to treat depressive disorders in inpatient psychiatry and to analyse the determinants of potential drug-drug interactions (pDDI) and potentially inappropriate medication (PIM).

Methods: Our study was part of a larger pharmacovigilance project funded by the German Innovation Funds. It included all inpatients with a main diagnosis in the group of depressive episodes (F32, ICD-10) or recurrent depressive disorders (F33) discharged from eight psychiatric hospitals in Germany between 1 October 2017 and 30 September 2018 or between 1 January and 31 December 2019. Read More

View Article and Full-Text PDF

Comparative Efficacy and Acceptability of Anti-inflammatory Agents on Major Depressive Disorder: A Network Meta-Analysis.

Front Pharmacol 2021 1;12:691200. Epub 2021 Jul 1.

Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, China.

With the growing importance of research about the association between neuroinflammation and major depressive disorder (MDD), anti-inflammatory agents have been used as a new antidepressant therapy in clinical practice. We conducted a network meta-analysis (NMA) with up-to-date evidence to compare different anti-inflammatory agents for improving the treatment of MDD patients. To identify eligible randomized clinical trials, four databases (i. Read More

View Article and Full-Text PDF

A Digital Intervention for Primary Care Practitioners to Support Antidepressant Discontinuation (Advisor for Health Professionals): Development Study.

J Med Internet Res 2021 Jul 16;23(7):e25537. Epub 2021 Jul 16.

Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, United Kingdom.

Background: The number of people receiving antidepressants has increased in the past 3 decades, mainly because of people staying on them longer. However, in many cases long-term treatment is not evidence based and risks increasing side effects. Additionally, prompting general practitioners (GPs) to review medication does not improve the rate of appropriate discontinuation. Read More

View Article and Full-Text PDF

"Modified Schirmer Test in Assessment of Salivary Flow Rate Among Patients on Antidepressants": A Comparative Study.

J Int Soc Prev Community Dent 2021 May-Jun;11(3):287-293. Epub 2021 Jun 10.

Department of Oral Maxillofacial Pathology and Microbiology, Dr. B. R. Ambedkar Institute of Dental Sciences, Patna, Bihar, India.

Aims: The objective of this study was to assess salivary flow rate (SFR) among healthy subjects or patients on antidepressant drugs such as tricyclic antidepressants (TCAs) and selective serotinin reuptake inhibitors (SSRIs) by using the "Modified Schirmer Test" (MST). To evaluate and correlate salivary flow rate by using MST and comparing it with the spitting method in patients on antidepressants and healthy control subjects.

Materials And Methods: Data were collected from the patients visiting the dental college and the psychiatry department. Read More

View Article and Full-Text PDF

Trends in treatment for patients with depression in general practice in Norway, 2009-2015: nationwide registry-based cohort study (The Norwegian GP-DEP Study).

BMC Health Serv Res 2021 Jul 15;21(1):697. Epub 2021 Jul 15.

Research Unit for General Practice, NORCE Norwegian Research Centre, Årstadveien 17, N-5009, Bergen, Norway.

Background: Depression is highly prevalent, but knowledge is scarce as to whether increased public awareness and strengthened government focus on mental health have changed how general practitioners (GPs) help their depressed patients. This study aimed to examine national time trends in GP depression care and whether trends varied regarding patient gender, age, and comorbidity.

Methods: Nationwide registry-based cohort study, Norway. Read More

View Article and Full-Text PDF

Healthcare Resource Consumption and Related Costs of Patients Estimated with Treatment-Resistant Depression in Italy.

Clinicoecon Outcomes Res 2021 5;13:629-635. Epub 2021 Jul 5.

CliCon S.r.l., Health, Economics & Outcomes Research, Bologna, Italy.

Purpose: To analyse the healthcare resource consumption and related costs for the Italian National Health System of patients estimated to be affected by treatment-resistant depression (TRD) in Italy.

Patients And Methods: This was an observational retrospective study based on administrative databases, including those related to residential/semiresidential structures, of Veneto Region and the Local Health Unit of Bergamo in Italy (for a total of around 6 million health-assisted subjects). Between July 2011 and December 2017, all adult patients with a third antidepressant (AD) after ≥2 AD (each one with at least ≥4 weeks duration, ≥1 prescription at maximum dosage reported in datasheets, a grace period ≤30 days when switching AD and treatment maintained ≥9 months) were included. Read More

View Article and Full-Text PDF

The Relationship Between Anxiety, Depression and Treatment Adherence in Chronic Obstructive Pulmonary Disease: A Systematic Review.

Int J Chron Obstruct Pulmon Dis 2021 6;16:2001-2021. Epub 2021 Jul 6.

Heart-Respiratory Rehabilitation Unit, IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy.

Background: Almost half of the people with chronic obstructive pulmonary disease (COPD) do not adhere to the prescribed treatments and report anxiety and depression as comorbidities, resulting in higher rates of exacerbations, hospitalizations, and worse clinical outcomes.

Objective: This systematic review provided a synthesis of studies about the relationships between anxiety, depression, and adherence in people affected by COPD.

Methods: English language publications were searched in the PUBMED, SCOPUS, PsycInfo, Web of Science, PsycArticles, and Cochrane Library databases from December 2020 to March 2021, following PRISMA guidelines. Read More

View Article and Full-Text PDF

Clinical Characteristics and Histologic Features of Hysterectomy Specimens From Transmasculine Individuals.

Obstet Gynecol 2021 Jul;138(1):51-57

Department of Obstetrics and Gynecology, the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and the Department of Pathology, Anatomy, & Cell Biology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Objective: To describe the clinical characteristics of transmasculine individuals who underwent hysterectomy and characterize surgical pathology findings.

Methods: Under an institutional review board-approved protocol, transmasculine individuals who were undergoing hysterectomy and bilateral salpingectomy or bilateral salpingo-oophorectomy were retrospectively identified from a single institution. Past medical, surgical, obstetric, and gynecologic history were collected, including prior testosterone use, cervical cancer screening status, and preoperative pelvic imaging. Read More

View Article and Full-Text PDF

Risk of fracture in antidepressant users with concurrent use of benzodiazepines: A self-controlled case-series analysis.

Bone 2021 Jul 10;153:116109. Epub 2021 Jul 10.

College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea; Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of Korea. Electronic address:

Objective: Despite the fracture risk associated with both antidepressant (AD) medication and benzodiazepines (BDZs), they are commonly prescribed simultaneously. However, studies elucidating the effects of concurrent use of BDZs and ADs on the risk fracture are scant. The objective of this study was to evaluate the risk of fracture associated with concurrent use of BDZs in AD users, using a self-controlled case-series analysis. Read More

View Article and Full-Text PDF

Agitation in Dementia: Real-World Impact and Burden on Patients and the Healthcare System.

J Alzheimers Dis 2021 Jul 8. Epub 2021 Jul 8.

Adelphi Real World, Bollington, UK.

Background: At least 90%of patients with dementia experience behavioral or neuropsychiatric symptoms including agitation, psychotic symptoms, apathy, depression, and sleep disturbances. Agitation has been reported to be experienced by 60%of patients with mild cognitive impairment and 76%of patients with Alzheimer's disease.

Objective: We aimed to assess the impact of agitation in patients with dementia on healthcare resource utilization (HCRU) and healthcare costs. Read More

View Article and Full-Text PDF

Erectile and Ejaculatory Dysfunction Associated with Use of Psychotropic Drugs: A Systematic Review.

J Sex Med 2021 Jul 8. Epub 2021 Jul 8.

Department of Urology, IRCCS Ca' Granda Ospedale Maggiore Policlinico - University of Milan, Milan, Italy. Electronic address:

Background: Sexual dysfunction may be a side effect of treatment with antipsychotics, antidepressants, and other psychotropic drugs.

Aim: To review the evidence concerning male sexual dysfunctions in patients taking psychotropic drugs to provide specific information to nonpsychiatric physicians for the management of these dysfunctions.

Methods: A systematic search of Medline and Embase databases was performed up to October 15, 2020. Read More

View Article and Full-Text PDF

Portable light therapy in the treatment of unipolar non-seasonal major depressive disorder: study protocol for the LUMIDEP randomised controlled trial.

BMJ Open 2021 Jul 9;11(7):e049331. Epub 2021 Jul 9.

Pôle Hospitalo-Universitaire De Psychiatrie d'Adultes et d'Addictologie Du Grand Nancy, Centre Psychothérapique de Nancy, Laxou, Lorraine, France.

Introduction: Major depressive disorder (MDD) affects more than 264 million people worldwide and is associated with an impaired quality of life as well as a higher risk of mortality. Current routine treatments demonstrate limited effectiveness. Light therapy (LT) on its own or in combination with antidepressant treatments could be an effective treatment, but the use of conventional LT devices use is restrictive. Read More

View Article and Full-Text PDF

Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: A systematic review and network meta-analysis.

J Psychopharmacol 2021 Jul 9:2698811211030181. Epub 2021 Jul 9.

Scientific Research Center, Maoming People's Hospital, Maoming, China.

Background: Depression is considered as one of the most common neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) patients. Prescription of antidepressants is a current clinical practice well-established as the first-line treatment for such patients. Our study was aimed at systematically examining the evidence on the efficacy of antidepressants in the treatment of depression in AD patients. Read More

View Article and Full-Text PDF

Antidepressant effects of total iridoids of via the intestinal flora-blood-brain barrier pathway.

Pharm Biol 2021 Dec;59(1):912-921

School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, PR China.

Context: Jones [syn. DC, (Valerianaceae)] (VJJ) is used to treat depression.

Objective: To explore the effects of total iridoids of VJJ extract (TIV) on chronic unpredictable mild stress (CUMS) in mice. Read More

View Article and Full-Text PDF
December 2021

A fatal poisoning case of acetone cyanohydrin and citalopram.

Leg Med (Tokyo) 2021 Jun 26;53:101937. Epub 2021 Jun 26.

Department of Legal Medicine, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo 173-8605, Japan.

Acetone cyanohydrin (ACH) is a readily available source of cyanide and is widely used in basic and applied sciences. In toxicology, ACH is classified as extremely hazardous as it readily decomposes on contact with water, with the potential rapid release of highly toxic hydrogen cyanide (HCN). We report the case of a young woman found dead from the intentional ingestion of ACH and citalopram, an antidepressant of the selective serotonin reuptake inhibitor class. Read More

View Article and Full-Text PDF

Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.

J Affect Disord 2021 Jun 24;293:285-294. Epub 2021 Jun 24.

Mood Disorder Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence (CRTCE), Mississauga, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Canada; University of Toronto, Toronto, ON, Canada. Electronic address:

Background: In recent years, ketamine and esketamine treatment have demonstrated rapid antidepressant effects in adults with treatment-resistant depression (TRD). Hitherto, relatively few studies have reported the effect of ketamine/esketamine treatment on functional outcomes (e.g. Read More

View Article and Full-Text PDF

Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression.

Front Psychiatry 2021 18;12:673159. Epub 2021 Jun 18.

Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, United States.

The glutamatergic modulator ketamine rapidly reduces depressive symptoms in individuals with treatment-resistant major depressive disorder (TRD) and bipolar disorder. While its underlying mechanism of antidepressant action is not fully understood, modulating glutamatergically-mediated connectivity appears to be a critical component moderating antidepressant response. This double-blind, crossover, placebo-controlled study analyzed data from 19 drug-free individuals with TRD and 15 healthy volunteers who received a single intravenous infusion of ketamine hydrochloride (0. Read More

View Article and Full-Text PDF

An investigation into the anxiety-relieving and mood-enhancing effects of Echinacea angustifolia (EP107™): A randomised, double-blind, placebo-controlled study.

J Affect Disord 2021 Jun 24;293:229-237. Epub 2021 Jun 24.

Clinical Research Australia, Perth, Western Australia 6023, Australia; College of Science, Health, Engineering and Education, Murdoch University, Perth, Western Australia 6150, Australia.

Background: The acute anxiolytic effects of the echinacea angustifolia extract (EP107) have been demonstrated in two previous human trials. The goals of this study were to examine the anxiolytic and mood-enhancing effects of echinacea angustifolia over a longer duration with a larger sample size.

Methods: In this 6-week, 3-arm, parallel-group, double-blind, randomised controlled trial, 108 adults with mild-to-moderately severe anxiety were recruited and randomised to receive either a placebo, 20 mg, or 40 mg of echinacea angustifolia, twice daily. Read More

View Article and Full-Text PDF

Trajectories of change in chronic depression: Differences in self-criticism and somatic symptoms between users of antidepressants and nonmedicated patients.

J Couns Psychol 2021 Jul 1. Epub 2021 Jul 1.

Modum Bad Research Institute.

Objective: Depression is typically seen as composed of several factors (i.e., cognitive, affective, somatic) which may be targeted by different interventions (i. Read More

View Article and Full-Text PDF

Childhood dystonic reactions in the middle Black Sea region.

Sevgi Çirakli

Medicine (Baltimore) 2021 Jul;100(26):e26465

Ordu University, Faculty of Medicine, Department of Pediatrics, Division of Pediatric, Neurology, Ordu, Turkey.

Abstract: Acute dystonic reactions are a worrying reason for presentation to the pediatric emergency department and the pediatric neurology clinic in childhood. It must be diagnosed and treated quickly. The aim of this study was to examine the clinical presentations, etiological factors, and prognosis of patients presenting to our regional tertiary pediatric neurology clinic with a diagnosis of acute dystonic reactions in children. Read More

View Article and Full-Text PDF

[Executive functions and their role in predicting therapeutic response in patients with depressive disorders].

Zh Nevrol Psikhiatr Im S S Korsakova 2021 ;121(5):40-44

Mental Health Research Institute of the Tomsk National Research Medical Center of the Russian Academy of Science, Tomsk, Russia.

Objective: To identify differences in executive functions in patients with depressive disorders depending on their sensitivity to antidepressants.

Material And Methods: The study included 70 patients with depressive disorder. All patients received syndrome-induced psychopharmacotherapy, which included antidepressants and normotimics. Read More

View Article and Full-Text PDF

No difference in antidepressant prescription in rheumatoid arthritis and controls. Results from a population-based, matched inception cohort.

Scand J Rheumatol 2021 Jun 29:1-7. Epub 2021 Jun 29.

Research Unit, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark.

: Depression occurs at least two times more often in rheumatoid arthritis (RA) patients than in controls, but little is known about the treatment of depression in RA. The primary objective of this study was to compare the 1 year period prevalence of antidepressant prescription in patients with RA versus controls.: We included a retrospective inception cohort of 509 patients with incident RA and 2545 frequency-matched population controls ascertained from 1995 to 2002. Read More

View Article and Full-Text PDF

Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review.

Int J Neuropsychopharmacol 2021 Jun 25. Epub 2021 Jun 25.

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Background: The use of ketamine for depression has increased rapidly in the past decades. Ketamine is often prescribed as add-on to other drugs used in psychiatric patients, but clear information on drug-drug interactions is lacking. With this review we aim to provide an overview of the pharmacodynamic interactions between ketamine and mood stabilizers, benzodiazepines, monoamine oxidase-inhibitors (MAOIs), antipsychotics and psychostimulants. Read More

View Article and Full-Text PDF

History of depression is associated with worsened postoperative outcomes following colectomy.

Colorectal Dis 2021 Jun 24. Epub 2021 Jun 24.

Colorectal Research Unit, Ravitch Colorectal Division, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Aim: Depression is a prevalent disorder that is associated with adverse health outcomes, but an understanding of its effect in colorectal surgery remains limited. The purpose of this study was to examine the impact of history of depression among patients undergoing colectomy.

Method: United States patients from Marketscan (2010-2017) who underwent colectomy were included and stratified by whether they had a history of depression within the past year, defined as (1) a diagnosis of depression during the index admission, (2) a diagnosis of depression during any inpatient or (3) outpatient admission within the year, and/or (4) a pharmacy claim for an antidepressant within the year. Read More

View Article and Full-Text PDF